[미국특허]
Markers associated with arteriovascular events and methods of use thereof
원문보기
IPC분류정보
국가/구분
United States(US) Patent
등록
국제특허분류(IPC7판)
G01N-033/68
G06F-019/00
G01N-033/74
출원번호
US-0704286
(2015-05-05)
등록번호
US-9689880
(2017-06-27)
발명자
/ 주소
Urdea, Mickey S.
McKenna, Michael P.
Arensdorf, Patrick A.
출원인 / 주소
TRUE HEALTH IP LLC
대리인 / 주소
Perkins Coie LLP
인용정보
피인용 횟수 :
0인용 특허 :
126
초록▼
Disclosed are methods of identifying subjects with arteriovascular disease, subjects at risk for developing arteriovascular disease, methods of differentially diagnosing diseases associated with arteriovascular disease from other diseases or within sub-classifications of arteriovascular disease, met
Disclosed are methods of identifying subjects with arteriovascular disease, subjects at risk for developing arteriovascular disease, methods of differentially diagnosing diseases associated with arteriovascular disease from other diseases or within sub-classifications of arteriovascular disease, methods of evaluating the risk of arteriovascular events in patients with arteriovascular disease, methods of evaluating the effectiveness of treatments in subjects with arteriovascular disease, and methods of selecting therapies for treating arteriovascular disease.
대표청구항▼
1. A method for treating an asymptomatic cardiovascular subject or a previously undiagnosed cardiovascular subject determine to be at risk for a future arteriovascular event or disease comprising: providing a blood sample isolated from an asymptomatic cardiovascular subject or a previously undiagnos
1. A method for treating an asymptomatic cardiovascular subject or a previously undiagnosed cardiovascular subject determine to be at risk for a future arteriovascular event or disease comprising: providing a blood sample isolated from an asymptomatic cardiovascular subject or a previously undiagnosed cardiovascular subject;measuring at least four component ARTERIORISKMARKERS in the blood sample selected from one or more groups consisting of Core Markers I, Core Markers II, Traditional Laboratory Risk Factors, Supplemental Markers I, Supplemental Markers II, Additional Markers I, and Additional Markers II, wherein at least one component ARTERIORISKMARKER is adiponectin;calculating an index value from an output of a Support Vector Machine (SVM) model, wherein inputs to the model comprise the measurements, and further wherein the model was developed by fitting data from a longitudinal study of a selected population of individuals and the fitted data comprises levels of the biomarkers and an end point in the selected population of individuals, wherein a calculated area under the curve (AUC) of the model is greater than or equal to 0.70, and wherein the end point is the risk of the cardiovascular event or the cardiovascular event; andadministering to the subject a therapeutic or prophylactic agent. 2. The method of claim 1, wherein the index value is correlated with the risk of the cardiovascular event or the cardiovascular event. 3. The method of claim 2, wherein the risk evaluation comprises normalizing the component ARTERIORISKMARKER measurements to reference values. 4. The method of claim 1, further comprising measuring at least two component ARTERIORISKMARKERS within Core Markers I. 5. The method of claim 1, further comprising measuring at least two component ARTERIORISKMARKERS within Core Markers II. 6. The method of claim 1, further comprising measuring at least two component ARTERIORISKMARKERS within Traditional Laboratory Risk Factors. 7. The method of claim 1, further comprising measuring at least two component ARTERIORISKMARKERS within Clinical Parameters. 8. The method of claim 1, further comprising measuring at least two component ARTERIORISKMARKERS within Supplemental Markers I or Supplemental Markers II. 9. The method of claim 1, further comprising measuring at least two component ARTERIORISKMARKERS within Additional Markers I or Additional Markers II. 10. The method of claim 1, wherein the measurement of at least one of the biomarkers of the panel is unaffected by treatment of the subject with one or more therapeutic interventions. 11. The method of claim 1, wherein the measurement of at least one of the biomarkers of the panel is affected by treatment of the subject with one or more therapeutic interventions. 12. The method of claim 1, further comprising measuring or determining one or more clinical parameters chosen from age, body mass index (BMI), diabetes, diastolic blood pressure (DBP), family history (FamHX), hip (circumference), height (HT), ethnicity (RACE), systolic blood pressure (SBP), gender (SEX), smoking, waist (circumference), and weight (WT). 13. The method of claim 1, further comprising one or more additional biomarker chosen from POMC, HDLC, and VEGF. 14. A method for treating an asymptomatic cardiovascular subject or a previously undiagnosed cardiovascular subject comprising: administering to the subject a therapeutic or prophylactic agent, wherein the subject has been determined to be at risk of developing arteriovascular disease or a arteriovascular event by a method comprising:measuring at least four component ARTERIORISKMARKERS in the blood sample selected from one or more groups consisting of Core Markers I, Core Markers II, Traditional Laboratory Risk Factors, Supplemental Markers I, Supplemental Markers II, Additional Markers I, and Additional Markers II, wherein at least one component ARTERIORISKMARKER is adiponectin; andcalculating an index value from an output of a Support Vector Machine (SVM) model, wherein inputs to the model comprise the measurements, and further wherein the model was developed by fitting data from a longitudinal study of a selected population of individuals and the fitted data comprises levels of the biomarkers and an end point in the selected population of individuals, wherein a calculated area under the curve (AUC) of the model is greater than or equal to 0.70, and wherein the end point is the risk of the cardiovascular event or the cardiovascular event.
Bertolini Girogio (Milan ITX) Casagrande Cesare (Arese ITX) Santangelo Francesco (Milan ITX), 1,2,3-triazole compounds active as inhibitors of the enzyme HMG-CoA reductase and pharmaceutical compositions containing.
Black Cameron (Pointe Claire CAX) Leger Serge (Dollard des Ormeaux CAX) Prasit Petpiboon (Kirkland CAX) Wang Zhaoyin (Pierrefonds CAX) Hamel Pierre (Laval CAX) Han Yongxin (Kirkland CAX) Hughes Grego, 3,4-diaryl-2-hydroxy-2,5-dihydrofurans as prodrugs to COX-2 inhibitors.
Joshua Henry (Staten Island NY) Wilson Kenneth E. (Westfield NJ) Schwartz Michael S. (Glenside PA) Lee Ta J. (Lansdale PA) Stokker Gerald E. (Gwynedd Valley PA), 3-keto HMG-COA reductase inhibitors.
Joshua Henry (Staten Island NY) Wilson Kenneth E. (Westfield NJ) Schwartz Michael S. (Glenside PA) Lee Ta J. (Lansdale PA) Stokker Gerald E. (Gwynedd Valley PA), 3-keto HMG-CoA reductase inhibitors.
Chucholowski Alexander W. (Ypsilanti MI) Roth Bruce D. (Ann Arbor MI) Sliskovic Drago R. (Ypsilanti MI), 5-pyrimidinyl-3,5-dihydroxy-6-heptenoic acid compounds useful as inhibitors of cholesterol biosynthesis.
Chucholowski Alexander W. (Ypsilanti MI) Creswell Mark W. (Chelsea MI) Roth Bruce D. (Ann Arbor MI) Sliskovic Drago R. (Ypsilanti MI), 6-(((Substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis.
Chucholowski Alexander W. (Ypsilanti MI) Creswell Mark W. (Chelsea MI) Roth Bruce D. (Ann Arbor MI) Sliskovic Drago R. (Ypsilanti MI), 6-(((substituted)pyridin-3-yl)alkyl)-and alkenyl)-tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol biosynthesis.
Picard Joseph A. (Ann Arbor MI) Sliskovic Drago R. (Ypsilanti MI), 6-(2-(2-(Substituted amino)-3-quinolinyl) ethenyl and ethyl) tetrahydro-4-hydroxypyran-2-one inhibitors of cholesterol b.
Jendralla Heiner (Frankfurt am Main DEX) Wess Gnther (Erlensee DEX) Bartmann Wilhelm (Bad Soden am Taunus DEX) Beck Gerhard (Frankfurt am Main DEX), 6-phenoxymethyl-4-hydroxytetrahydropyran-2-ones and 6-thiphenoxymethyl-4-hydroxytetrahydropyran-2-ones and the correspon.
Kesseler Kurt (Soden am Taunus DEX) Bartmann Wilhelm (Soden am Taunus DEX) Wess Gnther (Erlensee DEX) Granzer Ernold (Kelkheim DEX), 7-substituted derivatives of 3,5-dihydroxyhept-6-ynoic acids and corresponding lactones and their use as hypercholeserol.
Harris Elbert E. (Westfield NJ) Patchett Arthur A. (Westfield NJ) Tristram Edward W. (Watchung NJ) Wyvratt Matthew J. (Mountainside NJ), Aminoacid derivatives as antihypertensives.
Lifer Sherryl L. (Indianapolis IN) Marshall Winston S. (Bargersville IN) Mohamadi Fariborz (Indianapolis IN) Reel Jon K. (Indianapolis IN) Simon Richard L. (Greenwood IN) Steinberg Mitchell I. (India, Angiotensin II antagonist 1,3-imidazoles and use thereas.
Chakravarty Prasun K. (Edison NJ) Greenlee William J. (Teaneck NJ) Mantlo Nathan B. (Westfield NJ) Patchett Arthur A. (Westfield NJ) Schoen William (Edison NJ) Walsh Thomas F. (Westfield NJ), Angiotensin II antagonists.
Hoffman William F. (Wilmington Lansdale PA) Smith Robert L. (Wilmington Lansdale PA) Willard Alvin K. (Wilmington DE), Antihypercholesterolemic compounds.
Mohlenbrock William C. (Del Mar CA) Farley Peter J. (Orinda CA) Frye Lawrence J. (Atherton CA) Trummell ; Jr. Donald E. (Daly City CA) Bostrom Alan G. (San Francisco CA), Apparatus and method for improved estimation of health resource consumption through use of diagnostic and/or procedure g.
Gauthier Jacques Y. (Laval CAX) Lau Cheuk K. (Ile Bizard CAX) LeBlanc Yves (Kirkland CAX) Li Chun-Sing (Dollard des Ormeaux CAX) Roy Patrick (Dollard des Ormeaux CAX) Therien Michel (Laval CAX) Wang , Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents.
Bertolini Giorgio (Sesto San Giovanni ITX) Casagrande Cesare (Arese ITX) Santangelo Francesco (Milano ITX), Beazimidazole compounds active as inhibitors of the cholesterol biosynthesis.
Helms Gregory L. (Fanwood NJ) Horn Wendy S. (Westfield NJ) Jones E. Tracy T. (Edison NJ) Linemeyer David L. (Westfield NJ), Cholesterol lowering agents.
MacConnell John G. (Watchung NJ) Arison Byron H. (Watchung NJ) Doss George A. (Westfield NJ) Monaghan Richard L. (Somerset NJ), Cholesterol lowering compounds.
Byrne Kevin M. (West Trenton NJ) Chen Shieh-Shung T. (Morganville NJ) Kaplan Louis (New City NY) MacConnell John G. (Westfield NJ) Petuch Brian R. (Florence NJ) White Raymond F. (Palmyia VA) Arison B, Cholesterol lowering compounds produced by directed biosynthesis.
Berger Gregory D. (Belle Mead NJ) Bergstrom James D. (Neshanic NJ) Biftu Tesfaye (Westfield NJ) Bugianesi Robert L. (Colonia NJ) Burk Robert M. (Laguna Beach CA) Girotra Narindar N. (Old Bridge NJ) K, Cholesterol-lowering agents.
Dufresne Claude (East Brunswick NJ) Guarro Josep (Tarragona NJ ESX) Huang Leeyuan (Watchung NJ) Kong Yu L. (Edison NJ) Lingham Russell B. (Watchung NJ) Meinz Maria S. (Somerset NJ) Silverman Keith C., Cholesterol-lowering agents.
Bertolini Giorgio (Sesto San Giovanni) Casagrande Cesare (Arese) Santangelo Francesco (Milan ITX), Compounds active as inhibitors of the cholesterol biosynthesis.
Prasit Petpiboon (Kirkland CAX) Guay Daniel (Iie Perrot CAX) Wang Zhaoyin (Pierrefonds CAX) Leger Serge (Dollar des Ormeaux CAX) Therien Michel (Laval CAX), Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2.
Black Cameron (Point Claire CAX) Grimm Erich (Baie D\Urfe CAX) Wang Zhaoyin (Pierrefonds CAX) Leger Serge (Dollard des Ormeaux CAX), Diaryl-5-oxygenated-2-(5H) -furanones as COX-2 inhibitors.
Regan John R. (Princeton NJ) Bruno Joseph G. (Sellersville PA) Neuenschwander Kent W. (Ambler PA) Kuhla Donald E. (Doylestown PA), HMG-COA reductase inhibitors.
Smith Robert L. (Lansdale PA) Halczenko Wasyl (Hatfield PA) Hartman George D. (Lansdale PA) Stokker Gerald E. (Gwynedd Valley PA) Inamine Edward S. (Rahway NJ) Hensens Otto D. (Red Bank NJ) Houck Dav, HMG-CoA reductase inhibitors.
Cromlish Wanda A. (Montreal CAX) Kennedy Brian P. (Kirkland CAX) O\Neill Gary (Dollard Des Ormeaux CAX) Vickers Philip J. (Pierrefonds CAX) Wong Elizabeth (Montreal CAX) Mancini Joseph A. (St. Leonar, Human cyclooxygenase-2 cDNA and assays for evaluating cyclooxygenase-2 activity.
Monaghan Richard L. (Somerset NJ) Alberts Alfred W. (Short Hills NJ) Hoffman Carl H. (Scotch Plains NJ) Albers-Schonberg George (Princeton NJ), Hypocholesteremic fermentation products and process of preparation.
Olukotun Adeove Y. (Hopewell NJ) Alexander John C. (Winnetka IL), Method for preventing a second heart attack employing an HMG CoA reductase inhibitor.
Skold Carl (Mountain View CA) Gould Dennis R. (San Gregorio CA) Ullman Edwin F. (Atherton CA), Methods for modulating ligand-receptor interactions and their application.
Cover William H. (Lansdale PA) Dabora Rebecca L. (Andover MA) Hong Anderson (Taipei WA TWX) Reeves Christopher (Mill Creek WA) Stieber Robert W. (Harrisonburg VA) Vinci Victor A. (Charlottesville VA), Mutant strains of Aspergillus terreus for producing 7-[1,2,6,7,8,8a(R)-hexa-hydro-2(S),6(R)-dimethyl-8(S)-hydr.
Lau Cheuk Kun (Ile Bizard CAX) Black Cameron (Pointe Claire CAX) Guay Daniel (Ile Perrot CAX) Gauthier Jacques-Yves (Laval CAX) LeBlanc Yves (Kirkland CAX) Roy Patrick (Dollard des Ormeaux CAX) Ducha, N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors.
Lau Cheuk K. (Ile Bizard CAX) Black Cameron (Pointe Claire CAX) Guay Daniel (Ile Perrot CAX) Gauthier Jacques Y. (Laval CAX) LeBlanc Yves (Kirkland CAX) Roy Patrick (Dollard des Ormeaux CAX) Ducharme, N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors.
Inamine Edward S. (Rahway NJ) Hensens Otto D. (Red Bank NJ) Houck David R. (Los Alamos NM) Lee Ta J. (Lansdale PA) Smith Robert L. (Lansdale PA) Halczenko Wasyl (Hatfield PA) Hartman George D. (Lansd, Novel HMG-CoA reductase inhibitors.
Heusser Christoph (Bottmingen CHX) Andreatta Rudolf H. (Allschwil CHX) Alkan Sefik (Riehen CHX) Wood Jeanette (Biel-Benken CHX), Novel monoclonal antibodies to human renin and hybridoma cells, processes for their preparation and their applications.
TenBrink Ruth E. (Kalamazoo MI), Novel renin inhibiting polypeptide analogs containing S-aryl-D- or L- or DL-cysteinyl, 3-(arylthio)lactic acid or 3-(ary.
Luly Jay R. (1021 Mayfair Libertyville IL 60048) Plattner Jacob J. (1120 Garfield Ave. Libertyville IL 60048) Kempf Dale J. (36151 N. Grand Oaks Ct. Gurnee ; IL 60031), Peptidylaminodiols.
Karanewsky Donald S. (East Windsor NJ) Biller Scott A. (Ewing NJ) Gordon Eric M. (Pennington NJ), Phosphorous-containing HMG-CoA reductase inhibitors, new intermediates and method.
Karanewsky Donald S. (East Windsor NJ) Badia Michael C. (Lawrenceville NJ) Biller Scott A. (Ewing NJ) Gordon Eric M. (Pennington NJ) Sofia Michael J. (Lawrenceville NJ), Phosphorus-containing HMG-COA reductase inhibitors, new intermediates and method.
Karanewsky Donald S. (East Windsor NJ) Badia Michael C. (Lawrenceville NJ) Biller Scott A. (Ewing NJ) Gordon Eric M. (Pennington NJ) Sofia Michael J. (Lawrenceville NJ), Phosphorus-containing HMG-CoA reductase inhibitors, new intermediates and method.
Attwood Michael R. (Hitchin GB2) Hassall Cedric H. (Harpenden GB2) Lambert Robert W. (Welwyn GB2) Lawton Geoffrey (Hitchin GB2) Redshaw Sally (Hitchin GB2), Pyridazo[1,2-a][1,2]diazepines.
Albright Jay D. (Nanuet NY) Frederick Charles (Upper Saddle River NJ) Levin Jeremy I. (Spring Valley NY) Sum Fuk-Wah (Pomona NY) Reich Marvin F. (Suffern NY), Renin inhibitors.
Doherty Annette M. (Ann Arbor MI) Hamilton Harriet W. (Chelsea MI) Hodges John C. (Ann Arbor MI) Repine Joseph T. (Ann Arbor MI) Sircar Ila (Ann Arbor MI), Renin inhibitors, method for using them, and compositions containing them.
Huang Leeyuan (Watchung NJ) Dunn ; Jr. Joseph (Parlin NJ) Koupal Lawrence (Colonia NJ) Liesch Jerrold (Princeton Junction NJ) Hensens Otto (Red Bank NJ) Woodruff H. Boyd (Watchung NJ), Renin-inhibitory pepstatin phenyl derivatives.
Kabadi Mohan B. (Marlboro NJ) Vivilecchia Richard V. (Rockaway NJ), Stabilized pharmaceutical compositions comprising an HMG-CoA reductase inhibitor compound.
Carini David J. (Wilmington DE) Duncia John Jonas V. (Newark DE) Wells Gregory J. (Wilmington DE), Substituted 1,2,3-triazole angiotensin II antagonists.
Regan John R. (Princeton NJ) Bruno Joseph G. (Sellersville PA) Neuenschwander Kent W. (Ambler PA), Substituted cyclohexene derivatives as HMG-CoA reductase inhibitors.
Blankley C. John (Ann Arbor MI) Hodges John C. (Ann Arbor MI) Kiely John S. (Ann Arbor MI) Klutchko Sylvester R. (Ann Arbor MI), Substituted diimidazo [1,5-a: 4′,5′-d]pyridines having antihypertensive activity.
Vincent Michel (Bagneux FRX) Remond Georges (Versailles FRX) Laubie Michel (Vaucresson FRX), Substituted iminodiacids, their preparation and pharmaceutical compositions containing them.
Ridker Paul ; Hennekens Charles H., Systemic inflammatory markers as diagnostic tools in the prevention of atherosclerotic diseases and as tools to aid in the selection of agents to be used for the prevention and treatment of atheroscl.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.